An observational study in Trismus, sponsored by Centre Hospitalier de Valence. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Centre Hospitalier de Valence · Observational
A monocentric Study to evaluate the french translation of Gothenburg Trismus Questionnaire (GTQ).
Trismus is defined as a limitation in the mouth/jaw-opening ability due to a reduced mandible mobility. Trismus can occur from benign jaw related conditions, often referred to as temporomandibular disorders (TMD). It can also result from local or metastatic tumor growth of head and neck (H\&N) tumors, and more importantly, as a debilitating side-effect to H\&N oncology treatment, especially radiotherapy
The Gothenburg Trismus Questionnaire (GTQ) is a Patient Reported Outcome, validated in English, portuguese and sweden language.
The aim of this study is to develop a new tool in french language and to evaluate the specific impact of trismus on quality of life .
107 studies on the registry are indexed under Trismus; 19 are open to participants now.
Browse Trismus studies →Centre Hospitalier de Valence is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient treated for trismus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient treated for trismus
Patient under guardianship, deprived of liberty, safeguard of justice
Gothenburg Trismus Questionnaire (GTQ)
patient Reported Outcome measure: score 0-4 (0 means a better outcome, 4 means a worse outcome.)
Time frame: once at inclusion
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier de Valence